|
|
|
|
|
| March 24,
2011 | ISSUE NUMBER 192 VOL 8 |
Commentary
Making Sense of Market Chaos
Pharma’s vision usually consists of a threefold commitment: to advance new science, serve the patient, and wrest reimbursement access from an even more myopic class of payers and providers. But is this enough?
Featured Case Studies:
 Infosys’ SAP Life Sciences Success stories
Success stories of SAP programs for large Life Sciences companies encompassing Transformational engagements, Upgrades, Support and Compliance Management – A must read for Life Sciences companies leveraging SAP for their business success.  Read more... |
Regulatory
Two of the ‘Most Promising’ Drugs in Europe Hit US Snag
AstraZeneca’s Brilinta and Pharming’s Ruconest, named by a Thomson Reuters report as two of the most promising drugs to watch this year, have been held up during FDA’s review process.
Featured Case Studies:
Improving Clinical Operations with Digital Signatures
The majority of large CROs and Pharmas are using digital signatures to speed clinical site initiation, reduce site monitoring reporting costs, and improve audit efficiency.  Watch this short video to learn how digital signatures enable these benefits and others. |
R&D
Where Have All the Scientists Gone?
A $280 billion opportunity is left behind each year due to the failure of pharmaceutical companies to retain their customers.
Europe
EU Clinical Trials Register Goes Live
The European Medicines Agency launches an online register offering—for the first time—public access to information on interventional clinical trials for medicines authorized in the 27 EU Member States.
|
 |
|
|
 // Achaogen (San Francisco), a biopharmaceutical company discovering and developing antibiotics for the treatment of life-threatening, multi-drug resistant (MDR) bacterial infections, announced the appointment of Kenneth J. Hillan, M.B. Ch.B., as Chief Medical Officer.
// Catalent Pharma Solutions (Somerset, N.J.) announced the appointment of Tim McFadden as Vice President/General Manager of Consumer Health, Softgel.
//
KaloBios Pharmaceuticals (San Francisco) announced two additions to its senior management team. Jonathan Leff, M.D., previously Vice President and Chief Medical Officer of Halozyme Therapeutics, has been named Chief Medical Officer. Gary A. Lyons, former President and Chief Executive Officer of Neurocrine Biosciences, has been elected to the KaloBios Board of Directors. |
|
|
|
|
|
 |
|
|
| |
 |
|
 |
| Pharm Exec 50: Which Company is primed to move into the Top 10 this year? |
|
|
|
|
You
are subscribed to %%list.name%% as %%emailaddr%%. Click here to unsubscribe or edit your member profile.
To
ensure delivery to your Inbox, please add us to your
address book. If you need help doing this, click
here.
Advanstar Communications provides certain customer contact data (such as customers' names, addresses, phone numbers and e-mail addresses) to third parties who wish to promote relevant products, services and other opportunities which may be of interest to you. If you do not want Advanstar Communications to make your contact information available to third parties for marketing purposes, simply call (toll free) 1-866-529-2922 at any time, or fax us at 1-218-740-6417. Outside the U.S., please phone 1-218-740-6395. Contact us by mail at Advanstar Communications Inc., 131 West First St., Duluth, MN 55802-2065, USA.
|
|
